ChatGPT Image Feb 10, 2026, 10_19_56 AM

Our Translational Research Platform for Neurological Disease

Talk to an Expert

SBH SCIENCESNeurological Disease Research Center

We partner with industry and academic institutions to support drug development across a broad range of neuroodegenerative disorders by providing comprehensive disease modeling state-of-the-art functional assays, and biomarker discovery and development services.

 

Our In-Vitro Models, Biomarker Platforms, and Functional Assays

We have developed a platform of functional assays in a growing range of in vitro models to support drug development programs for key indications in neurodegenerative disease drug development including:

  • Cognitive-Dominant Neurodegenerative Disorders
  • Movement-Dominant Neurodegenerative Disorders
  • Motor Neuron Diseases
  • Inflammatory Neurodegeneration
  • Rare and Genetic Neurodegenerative Disorders
ChatGPT Image Feb 10, 2026, 10_23_48 AM-1

Functional Assays

Primary Neurons and Neuroblastoma Cells

24-1

Cell Viability and Neuroprotection

24-2

Mitochondrial Function

24-3

Oxidative Stress

23-1

a-Synuclein Aggregation and Clearance

23-2-1

Apoptosis and Cell Death Pathways

24-4

Target Engagement and MOA Validation

22-1

Neuronal Differentiation

17-2

Autophagy Lysosomal Pathway

A New Way of Diagnosing Alzheimer's Disease

As of May 2025, the FDA cleared the first blood test [using human plasma] to help diagnose Alzheimer's disease. The test is Lumipulse G that is based on the measurement of the ration between the pTau217 to ß-Amyloid 1-42 in adults 55+ with cognitive symptoms. The test provides approx. 90% accuracy in identifying pathology. This non-invasive test offers an alternative for positron emission tomography (PET) scans and cerebral spinal fluid (CSF) tests. For clarification: All our assays are run under RUO and not designed for human diagnostics. 
 
At SBH we have implemented pTau 217 testing that is based on the utilization of ELLA or SMCxPRO platform. See our data below. 
Screenshot 2026-03-11 at 7.28.47 PM

SMCxPRO

ELLA

We are currently validating the utilization of the ELLA for the analysis of β-Amyloid 1-40 and β-Amyloid 1-42 under CLIA. Shortly, all of these assays will be run under CLIA /GLP. 

Screenshot 2026-03-11 at 7.29.00 PM

Biofluid Protein Biomarkers

Biomarker Indication Biofluid
p-Tau217

Tau Phosphorylation (AD Specific)

 Plasma, CSF
p-Tau181

Tau Pathology

 Plasma, CSF

p-Tau231

Early Tau Changes

 Plasma, CSF

Aβ42

Amyloid Pathology

 CSF
Aβ42/40 Ratio

Amyloid Burden

 Plasma, CSF

Total Tau (t-Tau)

Neuronal Injury

 CSF, Plasma

GFAP

 Astrocytic Activatioon Plasma, CSF

NFL

 Axonal Degeneration Plasma, CSF
Neurogranin Synaptic Loss CSF
SNAP-25 Synaptic Dysfunction CSF